



**Workshop:**  
**The appropriate use of Tiered virus panels**  
**when assessing HIV-1 vaccine-elicited neutralizing antibodies**

New York, NY – July 7th, 2016

**Organized by the Global HIV Vaccine Enterprise:**

Gabriella Scarlatti, Science Director  
 Yegor Voronin, Senior Science Officer  
 Iris Corbasson, Program Assistant

**Science advisory committee:**

Pat D'Souza (DAIDS/NIAID)  
 Shan Lu (University of Massachusetts Medical School)  
 David Montefiori (Duke University Medical Center)

**Agenda**

<b>9:00 – 9:05</b>	<b>Welcome and Objectives</b> , <i>Gabriella Scarlatti (Global HIV Vaccine Enterprise)</i>
<b>9:05 – 9:15</b>	<b>Introductory Comments:</b> How did Tier phenotyping come about and what is it? <i>David Montefiori (Duke University Medical Center)</i>
<b>Session 1: History and Definition of Tiers</b>	
<b>Chair: Gabriella Scarlatti (Global HIV Vaccine Enterprise)</b>	
<b>9:15 – 9:30</b>	Defining Tiers, <i>Bette Korber (Los Alamos National Laboratory)</i>
<b>9:30 – 9:35</b>	Tiered-ness: a structural biology point of view, <i>Xiangpeng Kong (NYU School of Medicine)</i>
<b>9:35 – 10:45</b>	Discussion
<b>10:45 – 11:00</b>	Coffee break
<b>Session 2: The Utility of Tier 1 Viruses</b>	
<b>Chair: George Lewis (Institute of Human Virology)</b>	
<b>11:00 – 11:15</b>	A case for discarding testing of neutralization of Tier 1 viruses, <i>David Montefiori (Duke University Medical Center)</i>
<b>11:15 – 11:30</b>	Tier-1 panel: not ideal but useful, <i>Shan Lu (University of Massachusetts Medical School)</i>
<b>11:30 – 11:35</b>	Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection, <i>Ruth Ruprecht (Texas Biomedical Research Institute)</i>
<b>11:35 – 1:30</b>	Discussion
<b>1:30 – 2:15</b>	Lunch break
<b>Session 3: Looking Forward</b>	
<b>Chair: Susan Zolla-Pazner (Icahn School of Medicine at Mount Sinai)</b>	
<b>2:15 – 2:25</b>	Lessons learned from vaccine specific Influenza specific B cells, <i>Adrian McDermott (Vaccine Research Center, NIAID, NIH)</i>
<b>2:25 – 2:35</b>	Virus Panels for Assessing Vaccine Elicited Neutralizing Antibodies, <i>Mike Seaman (BIDMC/Harvard Medical School)</i>
<b>2:35 – 2:45</b>	Utilizing Real-Time Virus Panels to Characterize Vaccine Breadth, Potency and Escape? <i>Christos Petropoulos (LabCorp)</i>
<b>2:45 – 3:45</b>	Discussion
<b>3:45 – 4:00</b>	<b>Wrap up</b>